Crossref

1.

2. The Effect of Treatment and Bone Metabolic Factors on Fracture Incidence in Patients with Thalassemia-Induced Osteoporosis: An Observational Study

- Athanasios N. Tsartsalis

- George I. Lambrou

- Eugenia Vlachou

- Athanasia Samartzi

- George P. Chrousos

- Christina Kanaka-Gantenbein

- Antonis Kattamis

3. Open Reduction Internal Fixation vs Primary Arthrodesis for Lisfranc Fracture-Dislocations: A Cost Analysis

- Arinze Ochuba

- Christopher J. Murdock

- Amy L. Xu

- Morgan Snow

- Jessica Schmerler

- Christopher R. Leland

- Claire McDaniel

- John Thompson

- Amiethab A. Aiyer

4. Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis

- Friederike Thomasius

- Santiago Palacios

- Asif Alam

- Mitra Boolell

- Francis Vekeman

- Geneviève Gauthier

5. Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA

- John A. Eisman

- Bernard Cortet

- Mitra Boolell

- Raluca Ionescu-Ittu

- Francis Vekeman

- Julie Heroux

- Friederike Thomasius

6. PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis

- Charlotte Beaudart

- Nicola Veronese

- Jonathan Douxfils

- Jotheeswaran Amuthavalli Thiyagarajan

- Francesco Bolzetta

- Paolo Albanese

- Gianpaolo Voltan

- Majed Alokail

- Nicholas C. Harvey

- Nicholas R. Fuggle

- Olivier Bruyère

- René Rizzoli

- Jean-Yves Reginster